Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches

Signal Transduct Target Ther. 2020 Dec 24;5(1):293. doi: 10.1038/s41392-020-00454-7.

Abstract

On 12 March 2020, the outbreak of coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization. As of 4 August 2020, more than 18 million confirmed infections had been reported globally. Most patients have mild symptoms, but some patients develop respiratory failure which is the leading cause of death among COVID-19 patients. Endothelial cells with high levels of angiotensin-converting enzyme 2 expression are major participants and regulators of inflammatory reactions and coagulation. Accumulating evidence suggests that endothelial activation and dysfunction participate in COVID-19 pathogenesis by altering the integrity of vessel barrier, promoting pro-coagulative state, inducing endothelial inflammation, and even mediating leukocyte infiltration. This review describes the proposed cellular and molecular mechanisms of endothelial activation and dysfunction during COVID-19 emphasizing the principal mediators and therapeutic implications.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • COVID-19 / epidemiology*
  • COVID-19 / pathology
  • COVID-19 / virology
  • COVID-19 Drug Treatment
  • Endothelial Cells / pathology
  • Endothelial Cells / virology*
  • Humans
  • Inflammation / epidemiology*
  • Inflammation / virology
  • Pandemics*
  • Renin-Angiotensin System / genetics
  • SARS-CoV-2 / drug effects
  • SARS-CoV-2 / pathogenicity

Substances

  • Angiotensin-Converting Enzyme Inhibitors